Published 4 days ago • loading... • Updated 4 days ago

Celonic Group to manufacture monoclonal antibody for LINDIS Biotech

Summary by BioProcess International

The companies signed a multi-year contract, under which Celonic will manufacture a malignant ascite drug at its GMP facility in Germany.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

BioProcess International

Celonic Group to manufacture monoclonal antibody for LINDIS Biotech

The companies signed a multi-year contract, under which Celonic will manufacture a malignant ascite drug at its GMP facility in Germany.

4 days ago

Read Full Article

european-biotechnology.com

Lindis Biotech selects Celonic Group for commercial manufacturing of catumaxomab - European Biotechnology Magazine

LINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply. The post Lindis Biotech selects Celonic Group for commercial manufacturing of catumaxomab appeared first on European Biotechnology Magazine.

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right